Bone complications among prostate cancer survivors: Long-term follow-up from the prostate cancer outcomes study

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 4, 2014, Pages 338-342

  Morgans, A K ^a   Fan, K H ^a,b   Koyama, T ^a,b   Albertsen, P C ^c   Goodman, M ^d   Hamilton, A S ^e   Hoffman, R M ^f   Stanford, J L ^g   Stroup, A M ^h   Penson, D F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f UNIVERSITY OF NEW MEXICO   (United States)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; GONADORELIN AGONIST; PARATHYROID HORMONE; VITAMIN D; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; CANCER SURVIVOR; CAUCASIAN; DRUG USE; FOLLOW UP; FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BONE; CANCER REGISTRY; COHORT ANALYSIS; DRUG EFFECTS; FRACTURES, BONE; INFORMATION PROCESSING; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE AND BONES; COHORT STUDIES; DATA COLLECTION; FRACTURES, BONE; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVORS;

EID: 84909950151     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.31     Document Type: Article

References (25)

1. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute: Bethesda, MD, USA. 2013. Available at: http://seer.cancer.gov/csr/1975-2010/(last accessed 23 July 2013).
2. Smith MR. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-254.
3. Shahinian VB, Kuo Y, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352: 154-164.
4. Seeman E. The structural basis of bone fragility in men. Bone 1999; 25: 143-147.
5. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy X-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 2002; 167: 2361-2367.
6. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostate carcinoma. J Urol 1999; 161: 1219-1222.
7. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181-186.
8. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 1998; 83: 1561-1566.
9. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: A claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 7897-7903.
10. Potosky AL, Harlan LC, Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC et al. Prostate cancer practice patterns and quality of life: The Prostate Cancer Outcomes Study. J Natl Cancer Inst 1999; 91: 1719-1724.
11. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000; 92: 1582-1592.
12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
13. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267.
14. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004; 96: 1358-1367.
15. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. and the Urologic Diseases in American Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007; 110: 1493-1500.
16. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Euro Urol 2008; 54: 816-824.
17. Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer, a meta-analysis of randomized trials. JAMA 2011; 306: 2359-2366.
18. R Development Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2012. Available at: http://www.R-project.org/(last accessed 15 May 2013).
19. Lumley T. Survey: Analysis of Complex Survey Samples. R software package, v.3.28-2, 2012.
20. Lumley T. Analysis of complex survey samples. J Statist Softw 2004; 9: 1-19.
21. Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol 2012; 187: 889-893.
22. Morgans AK, Smith MR, O'Malley AJ, Keating NL. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy. Cancer 2013; 119: 863-870.
23. Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. J Urol 2010; 183: 2200-2205.
24. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Prostate Cancer, V.I.2010. Available at: http://www.indianacancer.org/resour ces/files/NCCN-2010-Prostate.pdf. (last accessed 23 July 2013).
25. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS et al. Long term functional outcomes after treatment for localized prostate cancer. N Engl J Med 2013; 368: 436-445.